Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“FDA Approval Alert!
Merck’s KEYTRUDA QLEX is now the 1st & only subcutaneous immune checkpoint inhibitor approved for adults across most solid tumor indications.
Administered in as little as 1–2 minutes (vs ~30 min IV)
Can be given in infusion centers, clinics, or doctor’s offices. Shown to have comparable efficacy & safety to IV pembrolizumab. A major step toward faster, more flexible cancer care.”
More posts featuring Yan Leyfman.